112 related articles for article (PubMed ID: 3047341)
1. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas.
Greenberg HS; Chandler WF; Diaz RF; Ensminger WD; Junck L; Page MA; Gebarski SS; McKeever P; Hood TW; Stetson PL
J Neurosurg; 1988 Oct; 69(4):500-5. PubMed ID: 3047341
[TBL] [Abstract][Full Text] [Related]
2. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas.
Hegarty TJ; Thornton AF; Diaz RF; Chandler WF; Ensminger WD; Junck L; Page MA; Gebarski SS; Hood TW; Stetson PL
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):421-8. PubMed ID: 2168357
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas.
Greenberg HS; Chandler WF; Ensminger WD; Sandler H; Junck L; Page MA; Crane D; McKeever P; Tankanow R; Bromberg J
Neurology; 1994 Sep; 44(9):1715-20. PubMed ID: 7936303
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors.
Matsutani M; Kohno T; Nagashima T; Nagayama I; Matsuda T; Hoshino T; Sano K
Radiat Med; 1988; 6(1):33-9. PubMed ID: 3045898
[TBL] [Abstract][Full Text] [Related]
5. Intra-arterial 5-bromo-2-deoxyuridine (BUdR) radiosensitization with external beam radiation in rhesus monkeys: toxicity study.
Greenberg HS; Chandler WF; Diaz RF; Averill DR; Gebarski SS; Lichter AS; Ensminger WD
J Neurooncol; 1988 Dec; 6(4):349-54. PubMed ID: 3221261
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
7. Mucocutaneous complications of intraarterial 5-bromodeoxyuridine and radiation.
McCuaig CC; Ellis CN; Greenberg HS; Hegarty TJ; Page MA
J Am Acad Dermatol; 1989 Dec; 21(6):1235-40. PubMed ID: 2584461
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.
Kinsella TJ; Russo A; Mitchell JB; Rowland J; Jenkins J; Schwade J; Myers CE; Collins JM; Speyer J; Kornblith P
Int J Radiat Oncol Biol Phys; 1984 Jan; 10(1):69-76. PubMed ID: 6321412
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
[TBL] [Abstract][Full Text] [Related]
10. Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study.
Eisbruch A; Robertson JM; Johnston CM; Tworek J; Reynolds KR; Roberts JA; Lawrence TS
J Clin Oncol; 1999 Jan; 17(1):31-40. PubMed ID: 10458215
[TBL] [Abstract][Full Text] [Related]
11. [A trial of ACNU and radiation therapy with sensitizing agents for malignant gliomas].
Kawano H; Hayashi M; Satoh K; Ishii H; Nakatsugawa S; Ishii Y
No To Shinkei; 1989 Nov; 41(11):1071-5. PubMed ID: 2620008
[TBL] [Abstract][Full Text] [Related]
12. BUdR radiosensitization in anaplastic astrocytoma.
Yung WK
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1105-6. PubMed ID: 10613300
[No Abstract] [Full Text] [Related]
13. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy.
Liang BC; Thornton AF; Sandler HM; Greenberg HS
J Neurosurg; 1991 Oct; 75(4):559-63. PubMed ID: 1653309
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas.
Hoshino T; Prados M; Wilson CB; Cho KG; Lee KS; Davis RL
J Neurosurg; 1989 Sep; 71(3):335-41. PubMed ID: 2549222
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors.
Phuphanich S; Levin EM; Levin VA
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1769-72. PubMed ID: 6480461
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
17. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
18. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers.
Kinsella TJ; Mitchell JB; Russo A; Morstyn G; Glatstein E
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1399-406. PubMed ID: 6381432
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
Levin VA; Prados MR; Wara WM; Davis RL; Gutin PH; Phillips TL; Lamborn K; Wilson CB
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):75-83. PubMed ID: 7721642
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization of hematopoietic precursor cells (CFUc) in glioblastoma patients receiving intermittent intravenous infusions of bromodeoxyuridine (BUdR).
Mitchell JB; Kinsella TJ; Russo A; McPherson S; Rowland J; Smith BH; Kornblith PL; Glatstein E
Int J Radiat Oncol Biol Phys; 1983 Apr; 9(4):457-63. PubMed ID: 6303991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
